Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity | Business Wire
The Use of Topical Nitroglycerin Ointment to Treat Peripheral Tissue Ischemia Secondary to Arterial Line Complications in Neonates | Journal of Perinatology
Dosage and Administration for RECTIV (nitroglycerin) Ointment